These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21816362)

  • 1. Inducing iPSCs to escape the dish.
    Barrilleaux B; Knoepfler PS
    Cell Stem Cell; 2011 Aug; 9(2):103-11. PubMed ID: 21816362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of human allogeneic and syngeneic pluripotent stem cells and immunological implications for transplantation.
    Sackett SD; Brown ME; Tremmel DM; Ellis T; Burlingham WJ; Odorico JS
    Transplant Rev (Orlando); 2016 Apr; 30(2):61-70. PubMed ID: 26970668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induced pluripotent stem cell-derived gamete-associated proteins incite rejection of induced pluripotent stem cells in syngeneic mice.
    Kim EM; Manzar G; Zavazava N
    Immunology; 2017 Jun; 151(2):191-197. PubMed ID: 28185259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced wound healing promotion by immune response-free monkey autologous iPSCs and exosomes vs. their allogeneic counterparts.
    Lu M; Peng L; Ming X; Wang X; Cui A; Li Y; Wang X; Meng D; Sun N; Xiang M; Chen S
    EBioMedicine; 2019 Apr; 42():443-457. PubMed ID: 30926422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of induced pluripotent stem cells.
    Zhao T; Zhang ZN; Rong Z; Xu Y
    Nature; 2011 May; 474(7350):212-5. PubMed ID: 21572395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redox and Epigenetics in Human Pluripotent Stem Cells Differentiation.
    Giallongo S; Rehakova D; Raffaele M; Lo Re O; Koutna I; Vinciguerra M
    Antioxid Redox Signal; 2021 Feb; 34(4):335-349. PubMed ID: 32567336
    [No Abstract]   [Full Text] [Related]  

  • 7. The genomic stability of induced pluripotent stem cells.
    Chen Z; Zhao T; Xu Y
    Protein Cell; 2012 Apr; 3(4):271-7. PubMed ID: 22528751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Obstacles to Clinical Translation of iPSCs.
    Tapia N; Schöler HR
    Cell Stem Cell; 2016 Sep; 19(3):298-309. PubMed ID: 27452174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induced pluripotency and oncogenic transformation are related processes.
    Riggs JW; Barrilleaux BL; Varlakhanova N; Bush KM; Chan V; Knoepfler PS
    Stem Cells Dev; 2013 Jan; 22(1):37-50. PubMed ID: 22998387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human induced pluripotent stem cells--from mechanisms to clinical applications.
    Drews K; Jozefczuk J; Prigione A; Adjaye J
    J Mol Med (Berl); 2012 Jul; 90(7):735-45. PubMed ID: 22643868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Embryonic stem cells or induced pluripotent stem cells? A DNA integrity perspective.
    Bai Q; Desprat R; Klein B; Lemaître JM; De Vos J
    Curr Gene Ther; 2013 Apr; 13(2):93-8. PubMed ID: 23317057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The miR-302-Mediated Induction of Pluripotent Stem Cells (iPSC): Multiple Synergistic Reprogramming Mechanisms.
    Ying SY; Fang W; Lin SL
    Methods Mol Biol; 2018; 1733():283-304. PubMed ID: 29435941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical therapy using iPSCs: hopes and challenges.
    Lu X; Zhao T
    Genomics Proteomics Bioinformatics; 2013 Oct; 11(5):294-8. PubMed ID: 24060840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induced pluripotent stem cell consensus genes: implication for the risk of tumorigenesis and cancers in induced pluripotent stem cell therapy.
    Zhang G; Shang B; Yang P; Cao Z; Pan Y; Zhou Q
    Stem Cells Dev; 2012 Apr; 21(6):955-64. PubMed ID: 22185567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cells derived from iPSC can be immunogenic - yes or no?
    Cao J; Li X; Lu X; Zhang C; Yu H; Zhao T
    Protein Cell; 2014 Jan; 5(1):1-3. PubMed ID: 24474200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells.
    Guha P; Morgan JW; Mostoslavsky G; Rodrigues NP; Boyd AS
    Cell Stem Cell; 2013 Apr; 12(4):407-12. PubMed ID: 23352605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and epigenetic variations in iPSCs: potential causes and implications for application.
    Liang G; Zhang Y
    Cell Stem Cell; 2013 Aug; 13(2):149-59. PubMed ID: 23910082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs.
    Menon S; Shailendra S; Renda A; Longaker M; Quarto N
    Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26805822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential for immunogenicity of autologous induced pluripotent stem cell-derived therapies.
    Scheiner ZS; Talib S; Feigal EG
    J Biol Chem; 2014 Feb; 289(8):4571-7. PubMed ID: 24362036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-Free Transplantation of Patient-Derived Induced Pluripotent Stem Cell Progeny for Customized Islet Regeneration.
    El Khatib MM; Ohmine S; Jacobus EJ; Tonne JM; Morsy SG; Holditch SJ; Schreiber CA; Uetsuka K; Fusaki N; Wigle DA; Terzic A; Kudva YC; Ikeda Y
    Stem Cells Transl Med; 2016 May; 5(5):694-702. PubMed ID: 26987352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.